Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of budesonide for intestinal acute GVHD after allogeneic HSCT
jRCTs021210039Phase 2Completed
- Sponsor
- Akita University Hospital
- Start
- Sep 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of budesonide in graft-versus-host disease (GVHD), sponsored by Akita University Hospital. Primary endpoint: Overall response rate at 28 days. Started Sep 2021; status: completed.
02
Drugs
budesonide
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on jRCTs021210039.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021210039.